

Consent to certain actions for the purposes of the Initial Enforcement Order made by the Competition and Markets Authority (CMA) on 1 April 2016

Completed acquisition by AAH Pharmaceuticals Limited (AAH) of Medical Advisory Services For Travellers Abroad Limited and Sangers (Northern Ireland) Limited (MASTA-Sangers)

We refer to [redacted] and [redacted] emails of 7, 19, 26 April 2016 and 6 May 2016 requesting that the CMA consents to derogations to the Initial Enforcement Order of 1 April 2016 (the **Initial Order**). The terms defined in the Initial Order have the same meaning in this letter.

Under the Initial Order, save for written consent by the CMA, McKesson UK Finance I Limited and McKesson Corporation (together **McKesson Corporation**) and AAH are required to hold separate the MASTA-Sangers business from the McKesson Corporation business and refrain from taking any action which might prejudice a reference under section 22 of the Act or impede the taking of any remedial action following such a reference. After due consideration of your request for derogations from the Initial Order, based on the information received from you and in the particular circumstances of this case, AAH and McKesson Corporation may carry out the following actions, in respect of the specific paragraphs:

Paragraphs 5(l)

For the purpose of determining the purchase price of the MASTA-Sangers business, McKesson Corporation and/or its subsidiary may need to have access to certain information relating to the accounts of MASTA-Sangers business, which may be considered as confidential. Providing that the information received by the individuals mentioned below will not be disclosed to any other individual carrying out activities within the McKesson Corporation and/or its subsidiaries, the CMA authorises :

- [redacted]
- [redacted]
- [redacted]

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

to receive the accounts information of MASTA-Sangers business in the form of “Pro-Forma Completion Accounts” as provided by [REDACTED] in her email of 7 April 2016 purely for the purpose of facilitating reconciliations and adjustments to the purchase price in order to finalise the transaction. In order to comply with this requirement, [REDACTED] will sign a non-disclosure agreement (NDA) in a form approved by the CMA.